CanSino Biologics
CanSino Biologics
CanSino Biologics Inc. is a Chinese biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccine products for human use. The company is known for its innovative approach to vaccine development and has gained international recognition for its work on the COVID-19 pandemic.
History
CanSino Biologics was founded in 2009 in Tianjin, China. The company was established by a group of scientists with extensive experience in the vaccine industry, aiming to develop high-quality vaccines for the global market. Since its inception, CanSino has focused on developing vaccines for infectious diseases, including tuberculosis, meningitis, and Ebola virus disease.
COVID-19 Vaccine Development
During the COVID-19 pandemic, CanSino Biologics developed a COVID-19 vaccine known as Convidecia. This vaccine is based on a recombinant adenovirus type-5 vector (Ad5) and was one of the first COVID-19 vaccines to be approved for emergency use in China. Convidecia is administered as a single-dose vaccine, which differentiates it from many other COVID-19 vaccines that require two doses.
Technology and Innovation
CanSino Biologics utilizes advanced technologies in its vaccine development processes. The company employs recombinant DNA technology and viral vector platforms to create effective and safe vaccines. The use of adenovirus vectors, such as in the Convidecia vaccine, allows for the delivery of genetic material into host cells, prompting an immune response without causing disease.
Global Impact
CanSino's Convidecia vaccine has been distributed to several countries around the world, contributing to the global effort to combat the COVID-19 pandemic. The vaccine's single-dose regimen and ease of storage and transportation have made it an attractive option for many countries, particularly those with limited healthcare infrastructure.
Related Pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
